Our new tagline “Chemistry that delivers” captures the core of our offer: deep expertise in synthetic chemistry and scale-up, applied with rigour and purpose to deliver reliable outcomes. It speaks to our chemistry-first approach and our ability to support science-led organisations across pharmaceuticals, diagnostics, and advanced materials, not just in theory, but in practice. Just as importantly, HFR remains a highly collaborative partner. Our director-led model and long-standing relationships mean you work directly with experienced chemists who understand your challenges and are invested in your success. That hands-on partnership continues to be central to how we operate.
HistologiX is a leading GLP/GCP compliant CRO supporting tissue based evaluation of your biomarkers; they help you visualise and understand what your drug or device is doing to your key biomarkers at the cellular and tissue level. Their experienced scientific team work as an extension of your in-house team and provide specialist histology, immunohistochemistry (IHC) including multiplex immunofluorescence (IF), multiplex in situ hybridisation (ISH) using RNAScope, digital pathology and image analysis services.
hVIVO plc (Ticker: HVO) is a science led drug development partner purpose-built to meet the growing complexity of modern clinical research. The Company operates an integrated end-to-end ecosystem that combines specialist clinical sites, advanced virology and immunology laboratories, human challenge expertise, and early drug development consulting. This unified model enables sponsors to generate rigorous, decision ready human data earlier in development, reducing uncertainty and accelerating progression through Phase I and II trials.
With industry‑leading capabilities in respiratory and infectious disease, alongside expanding expertise in cardiometabolic and other high‑growth therapeutic areas, hVIVO supports a diverse global client base that includes seven of the world’s ten largest biopharmaceutical companies. Its London quarantine facilities are the largest purpose‑built human challenge units in the world, complemented by additional early‑phase clinical capacity in Germany and a specialist consulting team providing strategic, regulatory, and biometry expertise.
The Company’s integrated approach delivers a seamless pathway from preclinical planning through early proof‑of‑concept, supported by continuous patient recruitment through FluCamp and a network of outpatient clinical sites for Phase II and III studies. By unifying scientific insight, operational control, and advanced laboratory capabilities, hVIVO provides sponsors with the clarity, speed, and reliability required to advance new medicines with confidence.
